Valeant

Teva looks to sell generics in China through joint venture with Guangzhou Pharma As the world’s largest generics maker, Teva still doesn’t have much of a presence in China, even though it is a country relies heavily on generics. The Israeli company is looking to remedy that as Teva has said it “has no agreement with...

Takeda scores blockbuster Velcade patent reprieve till 2022 In a major lift for Takeda and its aging multiple myeloma blockbuster Velcade, a U.S. appeals court overturned a ruling that invalidated a key patent, granting new exclusivity that should translate to significant sales over time. Takeda will have exclusive ...

Merck beats Q1 estimates as Keytruda sales double Merck is the victim of its own success, judging from its first-quarter report. The company beat sales and earnings estimates, and it upped its guidance for the year, despite some significant suffering from generic competition. Sales of its hit immuno-oncology drug Ke...

With $496M CNS sale, Novartis joins other Pharma companies casting off tired meds The latest Big Pharma to join the asset-sale party is Novartis, which is in talks to offload some of its older central nervous system (CNS) drugs, including Ritalin for attention deficit disorder and Exelon patch for Alzheimer’s. The p...